{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:21:54Z","timestamp":1781724114346,"version":"3.54.5"},"reference-count":254,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T00:00:00Z","timestamp":1407110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.bcp.2014.07.018","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T22:46:49Z","timestamp":1406674009000},"page":"73-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":548,"title":["Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR\u03b3): a review"],"prefix":"10.1016","volume":"92","author":[{"given":"Limei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Waltenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Pferschy-Wenzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Blunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Malainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Blazevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schwaiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Rollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke H.","family":"Heiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Stuppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena M.","family":"Dirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2545-0967","authenticated-orcid":false,"given":"Atanas G.","family":"Atanasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2014.07.018_bib0005","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1753-0407.2010.00078.x","article-title":"Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US","volume":"2","author":"Ford","year":"2010","journal-title":"J Diabetes"},{"key":"10.1016\/j.bcp.2014.07.018_bib0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/met.2012.0122","article-title":"The prevalence of metabolic syndrome in children: a systematic review of the literature","volume":"11","author":"Friend","year":"2013","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.bcp.2014.07.018_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2014.07.018_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0025","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1111\/j.1749-6632.2012.06468.x","article-title":"Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering","volume":"1243","author":"Berenson","year":"2011","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bcp.2014.07.018_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/092986708783330656","article-title":"Avery MA. Type 2 diabetes and oral antihyperglycemic drugs","volume":"15","author":"Mizuno","year":"2008","journal-title":"Curr Med Chem"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2014.07.018_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1463-1326.2011.01507.x","article-title":"Treating diabetes today: a matter of selectivity of sulphonylureas","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bcp.2014.07.018_bib0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2010.12.008","article-title":"NF-kappaB, inflammation, and metabolic disease","volume":"13","author":"Baker","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.bcp.2014.07.018_bib0045","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14728222.2010.528395","article-title":"Mitogen-activated protein kinase phosphatase-1 - a potential therapeutic target in metabolic disease","volume":"14","author":"Roth Flach","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bcp.2014.07.018_bib0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nat Rev Drug Discovery"},{"issue":"Suppl","key":"10.1016\/j.bcp.2014.07.018_bib0055","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1194\/jlr.R800079-JLR200","article-title":"Fatty acid metabolism: target for metabolic syndrome","volume":"50","author":"Wakil","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd3055","article-title":"Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases","volume":"9","author":"Cao","year":"2010","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bcp.2014.07.018_bib0065","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tips.2005.03.003","article-title":"PPARs: therapeutic targets for metabolic disease","volume":"26","author":"Berger","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2014.07.018_bib0070","doi-asserted-by":"crossref","first-page":"549627","DOI":"10.1155\/2013\/549627","article-title":"Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases","volume":"2013","author":"Monsalve","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.bcp.2014.07.018_bib0075","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/j.1460-2075.1992.tb05139.x","article-title":"Evolution of the nuclear receptor gene superfamily","volume":"11","author":"Laudet","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.bcp.2014.07.018_bib0080","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.07.018_bib0085","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0092-8674(92)90031-7","article-title":"Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors","volume":"68","author":"Dreyer","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2014.07.018_bib0090","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1073\/pnas.94.9.4312","article-title":"Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta","volume":"94","author":"Forman","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2014.07.018_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-6980(00)00071-X","article-title":"Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors","volume":"62","author":"Dussault","year":"2000","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bcp.2014.07.018_bib0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nm1025","article-title":"PPARs and the complex journey to obesity","volume":"10","author":"Evans","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0105","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1073\/pnas.90.4.1440","article-title":"Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor","volume":"90","author":"Gearing","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2014.07.018_bib0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.cellbio.12.1.335","article-title":"Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology","volume":"12","author":"Lemberger","year":"1996","journal-title":"Ann Rev Cell Dev Biol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0115","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.bbalip.2007.01.008","article-title":"Transcription coactivators for peroxisome proliferator-activated receptors","volume":"1771","author":"Yu","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2014.07.018_bib0120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.tcb.2007.04.001","article-title":"Transcriptional coregulators in the control of energy homeostasis","volume":"17","author":"Feige","year":"2007","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0125","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2337\/diab.46.8.1319","article-title":"Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients","volume":"46","author":"Auboeuf","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2014.07.018_bib0130","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bcp.2014.07.018_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","article-title":"Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease","volume":"205","author":"Fruchart","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bcp.2014.07.018_bib0140","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI27955","article-title":"PPAR delta: a dagger in the heart of the metabolic syndrome","volume":"116","author":"Barish","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2014.07.018_bib0145","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bbalip.2007.04.017","article-title":"Emerging roles of PPARdelta in metabolism","volume":"1771","author":"Seedorf","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2014.07.018_bib0150","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1073\/pnas.92.17.7921","article-title":"Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms","volume":"92","author":"Zhu","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2014.07.018_bib0155","doi-asserted-by":"crossref","first-page":"18779","DOI":"10.1074\/jbc.272.30.18779","article-title":"The organization, promoter analysis, and expression of the human PPARgamma gene","volume":"272","author":"Fajas","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0160","doi-asserted-by":"crossref","first-page":"20230","DOI":"10.1074\/jbc.272.32.20230","article-title":"Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin","volume":"272","author":"Werman","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0165","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1172\/JCI119424","article-title":"Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids","volume":"99","author":"Vidal-Puig","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2014.07.018_bib0170","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1371\/journal.pgen.0030064","article-title":"PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism","volume":"3","author":"Medina-Gomez","year":"2007","journal-title":"PLoS Genet"},{"key":"10.1016\/j.bcp.2014.07.018_bib0175","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.94.9.4318","article-title":"Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma","volume":"94","author":"Kliewer","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2014.07.018_bib0180","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Bio Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0185","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2174\/156802608786413474","article-title":"Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress","volume":"8","author":"Cho","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0190","doi-asserted-by":"crossref","first-page":"36093","DOI":"10.1074\/jbc.M405346200","article-title":"Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes","volume":"279","author":"Tzameli","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0195","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of PPARgamma","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2014.07.018_bib0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/18715303113139990003","article-title":"The need for physiologically relevant peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands","volume":"13","author":"Subramani","year":"2013","journal-title":"Endocr Metab Imm Disorders Drug Targets"},{"key":"10.1016\/j.bcp.2014.07.018_bib0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/BJ20101939","article-title":"Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARgamma agonist","volume":"438","author":"Goto","year":"2011","journal-title":"Biochem J"},{"key":"10.1016\/j.bcp.2014.07.018_bib0210","doi-asserted-by":"crossref","first-page":"12321","DOI":"10.1074\/jbc.M109.091512","article-title":"Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions","volume":"285","author":"Schopfer","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0215","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nsmb.1474","article-title":"Structural basis for the activation of PPARgamma by oxidized fatty acids","volume":"15","author":"Itoh","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0220","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0225","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0006-2952(03)00488-X","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation","volume":"66","author":"Na","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0230","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbalip.2007.03.006","article-title":"PPARgamma in human and mouse physiology","volume":"1771","author":"Heikkinen","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2014.07.018_bib0235","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1101\/gad.8.10.1224","article-title":"mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer","volume":"8","author":"Tontonoz","year":"1994","journal-title":"Genes Dev"},{"key":"10.1016\/j.bcp.2014.07.018_bib0240","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2014.07.018_bib0245","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1128\/MCB.16.7.3410","article-title":"Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma","volume":"16","author":"Sears","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0250","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1097-2765(00)80209-9","article-title":"PPAR gamma is required for placental, cardiac, and adipose tissue development","volume":"4","author":"Barak","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.bcp.2014.07.018_bib0255","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s001250051268","article-title":"PPARgamma, the ultimate thrifty gene","volume":"42","author":"Auwerx","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2014.07.018_bib0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mce.2009.09.014","article-title":"PPARs and adipocyte function","volume":"318","author":"Christodoulides","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0265","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.nutr.22.010402.102808","article-title":"PPAR(gamma) and glucose homeostasis","volume":"22","author":"Picard","year":"2002","journal-title":"Ann Rev Nutr"},{"key":"10.1016\/j.bcp.2014.07.018_bib0270","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPARgamma signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0275","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1196\/annals.1366.013","article-title":"PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function","volume":"1088","author":"Szatmari","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bcp.2014.07.018_bib0280","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbalip.2007.02.005","article-title":"PPARgamma in immunity and inflammation: cell types and diseases","volume":"1771","author":"Szeles","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2014.07.018_bib0285","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1161\/ATVBAHA.109.191189","article-title":"Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance","volume":"30","author":"Huang","year":"2010","journal-title":"Arterioscl Throm Vas Biol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0290","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nri2748","article-title":"Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells","volume":"10","author":"Glass","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0295","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.tem.2004.10.006","article-title":"Role of PPARgamma in macrophage biology and atherosclerosis","volume":"15","author":"Zhang","year":"2004","journal-title":"Trends Endocrinol Metabol: TEM"},{"key":"10.1016\/j.bcp.2014.07.018_bib0300","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/CAD.0b013e328011e67d","article-title":"Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics","volume":"18","author":"Han","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bcp.2014.07.018_bib0305","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1158\/1535-7163.MCT-10-0570","article-title":"Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition","volume":"9","author":"Reka","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2014.07.018_bib0310","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.07.018_bib0315","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1534-5807(03)00274-0","article-title":"Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity","volume":"5","author":"Rangwala","year":"2003","journal-title":"Dev Cell"},{"key":"10.1016\/j.bcp.2014.07.018_bib0320","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00109-001-0318-y","article-title":"Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home","volume":"80","author":"Fitzgerald","year":"2002","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.bcp.2014.07.018_bib0325","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/phrs.2001.0871","article-title":"PPARS, metabolic disease and atherosclerosis","volume":"44","author":"Fruchart","year":"2001","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0330","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/ATVBAHA.108.179689","article-title":"Fibrates, glitazones, and peroxisome proliferator-activated receptors","volume":"30","author":"Lalloyer","year":"2010","journal-title":"Arterioscl Thromb Vas Biol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0335","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2165\/00003495-200262100-00004","article-title":"Metabolic and additional vascular effects of thiazolidinediones","volume":"62","author":"Martens","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2014.07.018_bib0340","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1056\/NEJM199411033311803","article-title":"Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone","volume":"331","author":"Nolan","year":"1994","journal-title":"New England J Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0345","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/BF00418542","article-title":"Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group","volume":"39","author":"Kumar","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2014.07.018_bib0350","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2337\/diacare.19.2.151","article-title":"Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy","volume":"19","author":"Iwamoto","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2014.07.018_bib0355","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1172\/JCI119562","article-title":"Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance","volume":"100","author":"Cavaghan","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2014.07.018_bib0360","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJM199803263381302","article-title":"Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group","volume":"338","author":"Schwartz","year":"1998","journal-title":"New England J Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0365","doi-asserted-by":"crossref","first-page":"176","DOI":"10.7326\/0003-4819-128-3-199802010-00002","article-title":"Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Maggs","year":"1998","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0370","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s001250050948","article-title":"Insulin-induced vasodilatation and endothelial function in obesity\/insulin resistance. Effects of troglitazone","volume":"41","author":"Tack","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2014.07.018_bib0375","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/(SICI)1096-9136(199809)15:9<772::AID-DIA677>3.0.CO;2-X","article-title":"Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients","volume":"15","author":"Kumar","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0380","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1210\/jcem.83.5.4932","article-title":"Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes","volume":"83","author":"Minamikawa","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2014.07.018_bib0385","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0895-7061(95)96214-5","article-title":"Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives","volume":"8","author":"Ogihara","year":"1995","journal-title":"Am J Hypertension"},{"key":"10.1016\/j.bcp.2014.07.018_bib0390","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2337\/diab.46.3.433","article-title":"Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group","volume":"46","author":"Ghazzi","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2014.07.018_bib0395","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1056\/NEJM199803263381314","article-title":"Hepatic dysfunction associated with troglitazone","volume":"338","author":"Watkins","year":"1998","journal-title":"New England J Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0400","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1572-0241.2000.01707.x","article-title":"Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration","volume":"95","author":"Kohlroser","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0405","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7326\/0003-4819-129-1-199807010-00009","article-title":"Troglitazone-induced hepatic failure leading to liver transplantation. A case report","volume":"129","author":"Neuschwander-Tetri","year":"1998","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0410","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7326\/0003-4819-129-1-199807010-00008","article-title":"Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone","volume":"129","author":"Gitlin","year":"1998","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0415","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.2337\/diacare.21.12.2140","article-title":"An autopsy case of troglitazone-induced fulminant hepatitis","volume":"21","author":"Shibuya","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2014.07.018_bib0420","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/A:1005405526283","article-title":"Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group","volume":"45","author":"Murphy","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bcp.2014.07.018_bib0425","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(02)01529-2","article-title":"Troglitazone-induced liver failure: a case study","volume":"114","author":"Graham","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0430","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","article-title":"Rosiglitazone monotherapy is effective in patients with type 2 diabetes","volume":"86","author":"Lebovitz","year":"2001","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0435","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2337\/diacare.24.7.1226","article-title":"A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes","volume":"24","author":"Raskin","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2014.07.018_bib0440","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2337\/diacare.24.2.308","article-title":"Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes","volume":"24","author":"Phillips","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2014.07.018_bib0445","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2014.07.018_bib0450","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/diacare.26.1.172","article-title":"Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients","volume":"26","author":"Raji","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2014.07.018_bib0455","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"New England J Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0460","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2014.07.018_bib0465","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","article-title":"Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis","volume":"357","author":"Home","year":"2007","journal-title":"New England J Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0470","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2014.07.018_bib0475","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch Internal Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/0003-4819-132-2-200001180-00006","article-title":"Hepatocellular injury in a patient receiving rosiglitazone. A case report","volume":"132","author":"Al-Salman","year":"2000","journal-title":"Ann Int Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0485","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7326\/0003-4819-132-2-200001180-00005","article-title":"Hepatic failure in a patient taking rosiglitazone","volume":"132","author":"Forman","year":"2000","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0490","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1210\/jc.2002-020963","article-title":"Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study","volume":"87","author":"Fullert","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2014.07.018_bib0495","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2014.07.018_bib0500","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2014.07.018_bib0505","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2014.07.018_bib0510","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2014.07.018_bib0515","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study, The Pioglitazone 001 Study Group","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2014.07.018_bib0520","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","article-title":"Thiazolidinediones and PPARgamma agonists: time for a reassessment","volume":"23","author":"Cariou","year":"2012","journal-title":"Trends Endocrinol Metab: TEM"},{"key":"10.1016\/j.bcp.2014.07.018_bib0525","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/rheumatology\/keh423","article-title":"Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study","volume":"44","author":"Bongartz","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2014.07.018_bib0530","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/meta.2002.30506","article-title":"Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes","volume":"51","author":"Hirose","year":"2002","journal-title":"Metab: Clin Exp"},{"key":"10.1016\/j.bcp.2014.07.018_bib0535","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/j.1476-5381.2012.01938.x","article-title":"Submaximal PPARgamma activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders","volume":"166","author":"Balakumar","year":"2012","journal-title":"Brit J Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0540","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.2337\/diabetes.54.12.3442","article-title":"Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity","volume":"54","author":"Schupp","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2014.07.018_bib0545","doi-asserted-by":"crossref","first-page":"72S","DOI":"10.3945\/ajcn.2009.28449E","article-title":"Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation","volume":"91","author":"Higgins","year":"2010","journal-title":"Am J Clin Nut"},{"key":"10.1016\/j.bcp.2014.07.018_bib0550","doi-asserted-by":"crossref","first-page":"41626","DOI":"10.1074\/jbc.M111.257915","article-title":"N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor gamma ligand with partial and full agonist activity in vitro and in vivo","volume":"286","author":"Bhalla","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0555","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-3-642-17214-4_2","article-title":"Dual acting and pan-PPAR activators as potential anti-diabetic therapies","author":"Heald","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0560","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1475-2840-4-14","article-title":"Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons","volume":"4","author":"Tenenbaum","year":"2005","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0565","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1475-2840-11-140","article-title":"Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?","volume":"11","author":"Tenenbaum","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0570","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1210\/er.2003-0036","article-title":"Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology","volume":"25","author":"Knouff","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bcp.2014.07.018_bib0575","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph0911s46","article-title":"Natural products as a foundation for drug discovery","author":"Beutler","year":"2009","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0580","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.bbagen.2013.02.008","article-title":"Natural products: a continuing source of novel drug leads","volume":"1830","author":"Cragg","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2014.07.018_bib0585","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1039\/c3np70052f","article-title":"Matching the power of high throughput screening to the chemical diversity of natural products","volume":"30","author":"Henrich","year":"2013","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.bcp.2014.07.018_bib0590","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature03194","article-title":"Lessons from natural molecules","volume":"432","author":"Clardy","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.07.018_bib0595","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1021\/ci700286x","article-title":"Natural product-likeness score and its application for prioritization of compound libraries","volume":"48","author":"Ertl","year":"2008","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bcp.2014.07.018_bib0600","first-page":"965","article-title":"Medicinal plants in therapy","volume":"63","author":"Farnsworth","year":"1985","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.bcp.2014.07.018_bib0605","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/gme.0b013e31817062ce","article-title":"Red clover extract: a putative source for simultaneous treatment of menopausal disorders and the metabolic syndrome","volume":"15","author":"Mueller","year":"2008","journal-title":"Menopause"},{"key":"10.1016\/j.bcp.2014.07.018_bib0610","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jep.2013.06.007","article-title":"Ethnopharmacological in vitro studies on Austria's folk medicine--an unexplored lore in vitro anti-inflammatory activities of 71 Austrian traditional herbal drugs","volume":"149","author":"Vogl","year":"2013","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0615","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.phrs.2005.06.005","article-title":"Understanding local Mediterranean diets: a multidisciplinary pharmacological and ethnobotanical approach","volume":"52","author":"Local Food-Nutraceuticals Consortium","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0620","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/ptr.2782","article-title":"Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake","volume":"23","author":"Christensen","year":"2009","journal-title":"Phytother Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0625","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0033-1350620","article-title":"Screening of medicinal plants for PPARalpha and PPARgamma activation and evaluation of their effects on glucose uptake and 3T3-L1 adipogenesis","volume":"79","author":"Yang","year":"2013","journal-title":"Planta Medica"},{"key":"10.1016\/j.bcp.2014.07.018_bib0630","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1463-1326.2009.01131.x","article-title":"Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells","volume":"12","author":"Benhaddou-Andaloussi","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bcp.2014.07.018_bib0635","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.foodchem.2009.04.063","article-title":"Culinary plants, herbs and spices\u2013A rich source of PPAR\u03b3 ligands","volume":"117","author":"Mueller","year":"2009","journal-title":"Food Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0640","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jep.2014.01.029","article-title":"Activity-guided isolation of NF-kappaB inhibitors and PPARgamma agonists from the root bark of Lycium chinense Miller","volume":"152","author":"Xie","year":"2014","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0645","doi-asserted-by":"crossref","first-page":"395316","DOI":"10.1155\/2013\/395316","article-title":"The Herbal Drug Melampyrum pratense L. (Koch): Isolation and Identification of Its Bioactive Compounds Targeting Mediators of Inflammation","volume":"2013","author":"Vogl","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0650","doi-asserted-by":"crossref","first-page":"983023","DOI":"10.1155\/2012\/983023","article-title":"Selected Extracts of Chinese Herbal Medicines: Their Effect on NF-kappaB, PPARalpha and PPARgamma and the Respective Bioactive Compounds","volume":"2012","author":"Rozema","year":"2012","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0655","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10822-010-9398-5","article-title":"Pharmacophore-driven identification of PPARgamma agonists from natural sources","volume":"25","author":"Petersen","year":"2011","journal-title":"J Comput-Aid Mol Des"},{"key":"10.1016\/j.bcp.2014.07.018_bib0660","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jep.2010.07.054","article-title":"Activation of the nuclear receptor PPARgamma by metabolites isolated from sage (Salvia officinalis L.)","volume":"132","author":"Christensen","year":"2010","journal-title":"J Ethnopharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2014.07.018_bib0665","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1002\/ptr.3005","article-title":"Identification of bioactive compounds from flowers of black elder (Sambucus nigra L.) that activate the human peroxisome proliferator-activated receptor (PPAR) gamma","volume":"24","author":"Christensen","year":"2010","journal-title":"Phytother Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0670","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.lfs.2007.12.021","article-title":"Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity","volume":"82","author":"Fang","year":"2008","journal-title":"Life Sci"},{"key":"10.1016\/j.bcp.2014.07.018_bib0675","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1074\/jbc.M209483200","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein","volume":"278","author":"Dang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0680","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.bmcl.2003.09.052","article-title":"Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-A(y) mice","volume":"13","author":"Kuroda","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bcp.2014.07.018_bib0685","doi-asserted-by":"crossref","first-page":"11621","DOI":"10.1021\/jf802298w","article-title":"Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists","volume":"56","author":"Mueller","year":"2008","journal-title":"J Agr Food Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0690","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/jn\/136.4.899","article-title":"Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro","volume":"136","author":"Shen","year":"2006","journal-title":"J Nutr"},{"key":"10.1016\/j.bcp.2014.07.018_bib0695","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cmdc.200900469","article-title":"From machine learning to natural product derivatives that selectively activate transcription factor PPARgamma","volume":"5","author":"Rupp","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0700","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/mol.109.062141","article-title":"Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma","volume":"77","author":"Fakhrudin","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0705","doi-asserted-by":"crossref","first-page":"e24031","DOI":"10.1371\/journal.pone.0024031","article-title":"Dietary alpha-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-gamma","volume":"6","author":"Lewis","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2014.07.018_bib0710","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1747-0285.2007.00606.x","article-title":"Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study","volume":"71","author":"Salam","year":"2008","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bcp.2014.07.018_bib0715","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cbic.200800520","article-title":"Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists","volume":"10","author":"Tanrikulu","year":"2009","journal-title":"Chembiochem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0720","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jmb.2008.10.039","article-title":"Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids","volume":"385","author":"Waku","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0725","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2004.07.012","article-title":"An overview on biological mechanisms of PPARs","volume":"51","author":"Kota","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0730","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/01.RES.0000127122.22685.0A","article-title":"Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells","volume":"94","author":"Marx","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0735","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1367-5931(97)80015-4","article-title":"Peroxisome proliferator-activated receptor agonists","volume":"1","author":"Willson","year":"1997","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0740","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vph.2005.11.014","article-title":"Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications","volume":"45","author":"Touyz","year":"2006","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0745","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review","volume":"13","author":"Grygiel-Gorniak","year":"2014","journal-title":"Nutr J"},{"key":"10.1016\/j.bcp.2014.07.018_bib0750","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.58.4.5","article-title":"International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors","volume":"58","author":"Michalik","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2014.07.018_bib0755","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nature07202","article-title":"Integration of metabolism and inflammation by lipid-activated nuclear receptors","volume":"454","author":"Bensinger","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.07.018_bib0760","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/13543781003640169","article-title":"Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents","volume":"19","author":"Doshi","year":"2010","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1016\/j.bcp.2014.07.018_bib0765","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bbalip.2007.05.005","article-title":"The next generation of PPAR drugs: do we have the tools to find them","volume":"1771","author":"Shearer","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2014.07.018_bib0770","first-page":"2594","article-title":"[Study on effect of total saponins from Semen Nigellae on inflammatory mediators and ERK\/MAPK pathway in stimulated macrophage]","volume":"35","author":"Zhang","year":"2010","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"10.1016\/j.bcp.2014.07.018_bib0775","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/jf802737z","article-title":"Curcumin exerts antidifferentiation effect through AMPKalpha-PPAR-gamma in 3T3-L1 adipocytes and antiproliferatory effect through AMPKalpha-COX-2 in cancer cells","volume":"57","author":"Lee","year":"2009","journal-title":"J Agr Food Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0780","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbrc.2008.05.146","article-title":"Sakuranetin induces adipogenesis of 3T3-L1 cells through enhanced expression of PPARgamma2","volume":"372","author":"Saito","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2014.07.018_bib0785","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.taap.2004.12.009","article-title":"Anti-diabetic action of Punica granatum flower extract: activation of PPAR-gamma and identification of an active component","volume":"207","author":"Huang","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0790","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/aps.2009.113","article-title":"7-Chloroarctinone-b as a new selective PPARgamma antagonist potently blocks adipocyte differentiation","volume":"30","author":"Li","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bcp.2014.07.018_bib0795","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ptr.2606","article-title":"Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways","volume":"23","author":"Hwang","year":"2009","journal-title":"Phytother Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0800","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/oby.2008.472","article-title":"Isorhamnetin represses adipogenesis in 3T3-L1 cells","volume":"17","author":"Lee","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.bcp.2014.07.018_bib0805","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1210\/en.2008-0322","article-title":"The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism","volume":"150","author":"Gong","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2014.07.018_bib0810","doi-asserted-by":"crossref","first-page":"89369","DOI":"10.1155\/2007\/89369","article-title":"Mechanism of the anti-inflammatory effect of Curcumin: PPAR-gamma Activation","volume":"2007","author":"Jacob","year":"2007","journal-title":"PPAR Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0815","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/01.CCM.0000221921.71300.BF","article-title":"The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma","volume":"34","author":"Siddiqui","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0820","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0014-5793(02)02390-6","article-title":"Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes","volume":"514","author":"Takahashi","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bcp.2014.07.018_bib0825","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jmf.2007.0660","article-title":"Peroxisome proliferator-activated receptor activation by a short-term feeding of zingerone in aged rats","volume":"12","author":"Chung","year":"2009","journal-title":"J Med Food"},{"key":"10.1016\/j.bcp.2014.07.018_bib0830","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.febslet.2004.06.084","article-title":"Capsaicin inhibits the production of tumor necrosis factor alpha by LPS-stimulated murine macrophages, RAW 264.7: a PPARgamma ligand-like action as a novel mechanism","volume":"572","author":"Park","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bcp.2014.07.018_bib0835","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.intimp.2006.02.013","article-title":"Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma","volume":"6","author":"Zhang","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0840","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11010-011-0978-z","article-title":"Curcumin promotes cholesterol efflux from adipocytes related to PPARgamma-LXRalpha-ABCA1 passway","volume":"358","author":"Dong","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0845","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbrc.2007.11.119","article-title":"Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes","volume":"366","author":"Kuroyanagi","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2014.07.018_bib0850","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bbrc.2005.09.121","article-title":"Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma","volume":"337","author":"O'Sullivan","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2014.07.018_bib0855","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cmet.2007.03.010","article-title":"The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression","volume":"5","author":"Waki","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.bcp.2014.07.018_bib0860","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1016\/j.bmcl.2008.07.034","article-title":"Polychlorinated compounds with PPAR-gamma agonistic effect from the medicinal fungus Phellinus ribis","volume":"18","author":"Lee","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bcp.2014.07.018_bib0865","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/np050397q","article-title":"Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells","volume":"69","author":"Mora","year":"2006","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bcp.2014.07.018_bib0870","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbalip.2007.01.007","article-title":"Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators","volume":"1771","author":"Zoete","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2014.07.018_bib0875","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1016\/j.bbagen.2013.06.021","article-title":"Honokiol: a non-adipogenic PPARgamma agonist from nature","volume":"1830","author":"Atanasov","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2014.07.018_bib0880","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.lfs.2006.09.037","article-title":"Effects of magnolol (5,5\u2019-diallyl-2,2\u2019-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats","volume":"80","author":"Sohn","year":"2007","journal-title":"Life Sci"},{"key":"10.1016\/j.bcp.2014.07.018_bib0885","first-page":"R542","article-title":"Resveratrol supplementation improves white adipose tissue function in a depot-specific manner in Zucker diabetic fatty rats","volume":"305","author":"Beaudoin","year":"2013","journal-title":"Am J Physiol Reg I"},{"key":"10.1016\/j.bcp.2014.07.018_bib0890","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1743-7075-8-29","article-title":"Changes in white adipose tissue metabolism induced by resveratrol in rats","volume":"8","author":"Alberdi","year":"2011","journal-title":"Nutr Metab"},{"key":"10.1016\/j.bcp.2014.07.018_bib0895","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2010.29807","article-title":"Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-{alpha}-mediated inflammation and insulin resistance in primary human adipocytes","volume":"92","author":"Chuang","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.bcp.2014.07.018_bib0900","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.metabol.2008.04.006","article-title":"Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol","volume":"57","author":"Floyd","year":"2008","journal-title":"Metab: Clin Exp"},{"key":"10.1016\/j.bcp.2014.07.018_bib0905","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3892\/ijmm.2014.1680","article-title":"Inhibitory effects of resveratrol on foam cell formation are mediated through monocyte chemotactic protein-1 and lipid metabolism-related proteins","volume":"33","author":"Dong","year":"2014","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0910","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejphar.2012.08.024","article-title":"Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARgamma and adenosine","volume":"698","author":"Voloshyna","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0915","first-page":"729","article-title":"Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation","volume":"25","author":"Zhang","year":"2010","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.bcp.2014.07.018_bib0920","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1194\/jlr.M800258-JLR200","article-title":"Conjugated linoleic acid-mediated inflammation and insulin resistance in human adipocytes are attenuated by resveratrol","volume":"50","author":"Kennedy","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib0925","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.vph.2006.08.412","article-title":"Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma","volume":"46","author":"Ge","year":"2007","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0930","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S0007114511000316","article-title":"Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients","volume":"106","author":"Brasnyo","year":"2011","journal-title":"Brit J Nutr"},{"key":"10.1016\/j.bcp.2014.07.018_bib0935","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.1116971109","article-title":"Amorfrutins are potent antidiabetic dietary natural products","volume":"109","author":"Weidner","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2014.07.018_bib0940","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00125-013-2920-2","article-title":"Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARgamma) agonist with potent glucose-lowering properties","volume":"56","author":"Weidner","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2014.07.018_bib0945","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbrc.2013.01.083","article-title":"Anti-diabetic effect of amorphastilbol through PPARalpha\/gamma dual activation in db\/db mice","volume":"432","author":"Lee","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2014.07.018_bib0950","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/np100120c","article-title":"Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor","volume":"73","author":"Kotani","year":"2010","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bcp.2014.07.018_bib0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/bpb.35.1","article-title":"A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers","volume":"35","author":"Kotani","year":"2012","journal-title":"Biol Pharmaceut Bull"},{"key":"10.1016\/j.bcp.2014.07.018_bib0960","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1248\/bpb.33.1105","article-title":"Honokiol increases ABCA1 expression level by activating retinoid X receptor beta","volume":"33","author":"Jung","year":"2010","journal-title":"Biol Pharmaceut Bull"},{"key":"10.1016\/j.bcp.2014.07.018_bib0965","doi-asserted-by":"crossref","first-page":"e28253","DOI":"10.1371\/journal.pone.0028253","article-title":"Molecular determinants of magnolol targeting both RXRalpha and PPARgamma","volume":"6","author":"Zhang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2014.07.018_bib0970","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.lfs.2009.04.001","article-title":"Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells","volume":"84","author":"Choi","year":"2009","journal-title":"Life Sci"},{"key":"10.1016\/j.bcp.2014.07.018_bib0975","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/mol.111.076216","article-title":"Mode of peroxisome proliferator-activated receptor gamma activation by luteolin","volume":"81","author":"Puhl","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib0980","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/25931","article-title":"Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma","volume":"395","author":"Nolte","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.07.018_bib0985","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1021\/jm3013272","article-title":"Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor gamma","volume":"56","author":"de Groot","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib0990","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10822-011-9446-9","article-title":"Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity","volume":"25","author":"Guasch","year":"2011","journal-title":"J Comput-Aid Mol Des"},{"key":"10.1016\/j.bcp.2014.07.018_bib0995","doi-asserted-by":"crossref","first-page":"e36297","DOI":"10.1371\/journal.pone.0036297","article-title":"Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) gamma activators and pan-PPAR partial agonists","volume":"7","author":"Liberato","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2014.07.018_bib1000","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib1005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0378-8741(99)00154-3","article-title":"Inhibitor of tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW264.7 cells from Amorpha fruticosa","volume":"70","author":"Cho","year":"2000","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib1010","series-title":"Applied illustrated compendium of materia medica (Chinese-English edition)","author":"Gao Xuemin","year":"2006"},{"key":"10.1016\/j.bcp.2014.07.018_bib1015","series-title":"Indian Medicinal Plants: An Illustrated Dictionary","author":"Khare","year":"2007"},{"key":"10.1016\/j.bcp.2014.07.018_bib1020","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.bbrc.2009.10.162","article-title":"Bixin regulates mRNA expression involved in adipogenesis and enhances insulin sensitivity in 3T3-L1 adipocytes through PPARgamma activation","volume":"390","author":"Takahashi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2014.07.018_bib1025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bcp.2008.09.033","article-title":"(-)-Catechin promotes adipocyte differentiation in human bone marrow mesenchymal stem cells through PPAR gamma transactivation","volume":"77","author":"Shin","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib1030","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jep.2013.06.047","article-title":"Analysis of traditional knowledge in medicinal plants used by Yuan in Thailand","volume":"149","author":"Inta","year":"2013","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib1035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1055\/s-0029-1185386","article-title":"A peroxisome proliferator-activated receptor-gamma agonist and other constituents from Chromolaena odorata","volume":"75","author":"Dat","year":"2009","journal-title":"Planta Medica"},{"key":"10.1016\/j.bcp.2014.07.018_bib1040","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/np300386d","article-title":"PPARgamma agonist from Chromolaena odorata","volume":"75","author":"Zhang","year":"2012","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bcp.2014.07.018_bib1045","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1248\/bpb.32.735","article-title":"Peroxisome proliferator-activated receptor gamma ligands isolated from adlay seed (Coix lacryma-jobi L. var. ma-yuen STAPF.)","volume":"32","author":"Yokoi","year":"2009","journal-title":"Biol Pharmaceut Bull"},{"key":"10.1016\/j.bcp.2014.07.018_bib1050","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jnutbio.2008.07.010","article-title":"Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)\/Lep(ob) mice","volume":"20","author":"Cornick","year":"2009","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.bcp.2014.07.018_bib1055","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbagen.2012.02.004","article-title":"Liver X receptor and peroxisome proliferator-activated receptor agonist from Cornus alternifolia","volume":"1820","author":"He","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2014.07.018_bib1060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.lfs.2005.05.094","article-title":"Anthocyanins in Cornus alternifolia, Cornus controversa, Cornus kousa and Cornus florida fruits with health benefits","volume":"78","author":"Vareed","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.bcp.2014.07.018_bib1065","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.bbalip.2010.07.004","article-title":"Citral, a component of lemongrass oil, activates PPARalpha and gamma and suppresses COX-2 expression","volume":"1801","author":"Katsukawa","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2014.07.018_bib1070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000071678","article-title":"[History of a plant: the example of Echinacea]","volume":"10","author":"Hostettmann","year":"2003","journal-title":"Forsch Komplementarmed Klass Naturheilkd"},{"key":"10.1016\/j.bcp.2014.07.018_bib1075","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/np900003a","article-title":"Activation of PPARgamma by metabolites from the flowers of purple coneflower (Echinacea purpurea)","volume":"72","author":"Christensen","year":"2009","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bcp.2014.07.018_bib1080","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3390\/molecules15053186","article-title":"Wound healing potential of Elaeis guineensis Jacq leaves in an infected albino rat model","volume":"15","author":"Sasidharan","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2014.07.018_bib1085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/mnfr.200900119","article-title":"Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors","volume":"54","author":"Fang","year":"2010","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib1090","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.bcp.2007.11.021","article-title":"Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma","volume":"75","author":"Zou","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib1095","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.fitote.2012.02.003","article-title":"Acylated flavonol glycosides from Epimedium elatum, a plant endemic to the Western Himalayas","volume":"83","author":"Tantry","year":"2012","journal-title":"Fitoterapia"},{"key":"10.1016\/j.bcp.2014.07.018_bib1100","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.bmc.2009.11.027","article-title":"Phenolics from Glycyrrhiza glabra roots and their PPAR-gamma ligand-binding activity","volume":"18","author":"Kuroda","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bcp.2014.07.018_bib1105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1746-4269-9-59","article-title":"Botanical identification of medicinal roots collected and traded in Morocco and comparison to the existing literature","volume":"9","author":"Ouarghidi","year":"2013","journal-title":"J Ethnobiol Ethnomed"},{"key":"10.1016\/j.bcp.2014.07.018_bib1110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jnutbio.2011.03.021","article-title":"Licochalcone E has an antidiabetic effect","volume":"23","author":"Park","year":"2012","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.bcp.2014.07.018_bib1115","unstructured":"Sauvan N, Renimel I, Lamy C, Dupont D. Patent US 7527813 B2: Cosmetic composition containing an extract of Limnocitrus littoralis. Google Patents, 2009."},{"key":"10.1016\/j.bcp.2014.07.018_bib1120","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1055\/s-2007-990216","article-title":"Reverse pharmacognosy: identifying biological properties for plants by means of their molecule constituents: application to meranzin","volume":"73","author":"Do","year":"2007","journal-title":"Planta Medica"},{"key":"10.1016\/j.bcp.2014.07.018_bib1125","series-title":"China Pharmacopoeia (Part 1)","author":"Committee of National Pharmacopoeia","year":"2010"},{"key":"10.1016\/j.bcp.2014.07.018_bib1130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/jmf.2011.1766","article-title":"Inhibition of nuclear transcription factor-kappaB and activation of peroxisome proliferator-activated receptors in HepG2 cells by cucurbitane-type triterpene glycosides from Momordica charantia","volume":"15","author":"Nhiem","year":"2012","journal-title":"J Med Food"},{"key":"10.1016\/j.bcp.2014.07.018_bib1135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jep.2009.09.011","article-title":"Quantitative analysis of chemical constituents in different commercial parts of Notopterygium incisum by HPLC-DAD-MS","volume":"126","author":"Liu","year":"2009","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib1140","doi-asserted-by":"crossref","first-page":"e61755","DOI":"10.1371\/journal.pone.0061755","article-title":"Polyacetylenes from Notopterygium incisum--new selective partial agonists of peroxisome proliferator-activated receptor-gamma","volume":"8","author":"Atanasov","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2014.07.018_bib1145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1248\/bpb.29.110","article-title":"Ginsenoside 20S-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor gamma (PPARgamma) in 3T3-L1 adipocytes","volume":"29","author":"Han","year":"2006","journal-title":"Biol Pharmaceut Bull"},{"key":"10.1016\/j.bcp.2014.07.018_bib1150","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.lfs.2006.10.021","article-title":"Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhancing PPARgamma2 and C\/EBPalpha gene expression","volume":"80","author":"Shang","year":"2007","journal-title":"Life Sci"},{"key":"10.1016\/j.bcp.2014.07.018_bib1155","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-05-0209","article-title":"Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo","volume":"11","author":"Wong","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib1160","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1055\/s-2002-33785","article-title":"Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists","volume":"68","author":"Jaradat","year":"2002","journal-title":"Planta Medica"},{"key":"10.1016\/j.bcp.2014.07.018_bib1165","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jep.2011.02.001","article-title":"Kudzu root: traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases","volume":"134","author":"Wong","year":"2011","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib1170","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1016\/j.bmcl.2012.04.062","article-title":"Total synthesis and dual PPARalpha\/gamma agonist effects of amorphastilbol and its synthetic derivatives","volume":"22","author":"Kim","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bcp.2014.07.018_bib1175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1055\/s-2006-946680","article-title":"Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma","volume":"72","author":"Rau","year":"2006","journal-title":"Planta Medica"},{"key":"10.1016\/j.bcp.2014.07.018_bib1180","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/14786410701590657","article-title":"Effects of ethanol extract from Saururus chinensis (Bour.) Baill on lipid and antioxidant metabolisms in rats fed a high-fat diet","volume":"22","author":"Yu","year":"2008","journal-title":"Nat Prod Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib1185","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/np010440j","article-title":"Two new furanoditerpenes from Saururus chinenesis and their effects on the activation of peroxisome proliferator-activated receptor gamma","volume":"65","author":"Hwang","year":"2002","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bcp.2014.07.018_bib1190","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1021\/np400943b","article-title":"Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma","volume":"77","author":"Pferschy-Wenzig","year":"2014","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bcp.2014.07.018_bib1195","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14786419.2010.482053","article-title":"In vitro antioxidant activities of the methanol extract and its different solvent fractions obtained from the fruit pericarp of Terminalia bellerica","volume":"25","author":"Nampoothiri","year":"2011","journal-title":"Nat Prod Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib1200","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jep.2013.07.003","article-title":"Constituents from Terminalia species increase PPARalpha and PPARgamma levels and stimulate glucose uptake without enhancing adipocyte differentiation","volume":"149","author":"Yang","year":"2013","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bcp.2014.07.018_bib1205","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1194\/jlr.M900255-JLR200","article-title":"Carvacrol, a component of thyme oil, activates PPARalpha and gamma and suppresses COX-2 expression","volume":"51","author":"Hotta","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib1210","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1039\/C0FO00086H","article-title":"Red wine: a source of potent ligands for peroxisome proliferator-activated receptor gamma","volume":"2","author":"Zoechling","year":"2011","journal-title":"Food Funct"},{"key":"10.1016\/j.bcp.2014.07.018_bib1215","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1248\/bpb.25.81","article-title":"Dehydrotrametenolic acid induces preadipocyte differentiation and sensitizes animal models of noninsulin-dependent diabetes mellitus to insulin","volume":"25","author":"Sato","year":"2002","journal-title":"Biol Pharmaceut Bull"},{"key":"10.1016\/j.bcp.2014.07.018_bib1220","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbrc.2008.06.046","article-title":"6-Shogaol and 6-gingerol, the pungent of ginger, inhibit TNF-alpha mediated downregulation of adiponectin expression via different mechanisms in 3T3-L1 adipocytes","volume":"373","author":"Isa","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2014.07.018_bib1225","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.maturitas.2011.12.009","article-title":"Anti-inflammatory properties of culinary herbs and spices that ameliorate the effects of metabolic syndrome","volume":"71","author":"Jungbauer","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.bcp.2014.07.018_bib1230","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jn\/137.2.351","article-title":"Anti-inflammatory effects of isoflavones are dependent on flow and human endothelial cell PPARgamma","volume":"137","author":"Chacko","year":"2007","journal-title":"J Nutr"},{"key":"10.1016\/j.bcp.2014.07.018_bib1235","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/gme.0b013e3181c94617","article-title":"Red clover extract: a source for substances that activate peroxisome proliferator-activated receptor alpha and ameliorate the cytokine secretion profile of lipopolysaccharide-stimulated macrophages","volume":"17","author":"Mueller","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.bcp.2014.07.018_bib1240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mce.2004.03.011","article-title":"Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha","volume":"220","author":"Kim","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bcp.2014.07.018_bib1245","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/jn\/133.5.1238","article-title":"Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells","volume":"133","author":"Mezei","year":"2003","journal-title":"J Nutr"},{"key":"10.1016\/j.bcp.2014.07.018_bib1250","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.201300754","article-title":"Resveratrol and Its Metabolites Bind to PPARs","author":"Calleri","year":"2014","journal-title":"Chembiochem"},{"key":"10.1016\/j.bcp.2014.07.018_bib1255","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1158\/0008-5472.CAN-05-2777","article-title":"Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism","volume":"66","author":"Ulrich","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2014.07.018_bib1260","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1055\/s-0030-1250435","article-title":"PPARalpha activation by culinary herbs and spices","volume":"77","author":"Mueller","year":"2011","journal-title":"Planta Medica"},{"key":"10.1016\/j.bcp.2014.07.018_bib1265","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1016\/j.febslet.2008.09.011","article-title":"Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARalpha\/gamma activation in 3T3-L1 cells","volume":"582","author":"Kim","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bcp.2014.07.018_bib1270","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/ci049885e","article-title":"LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters","volume":"45","author":"Wolber","year":"2005","journal-title":"J Chem Inf Model"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214004249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214004249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T06:12:51Z","timestamp":1565676771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295214004249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":254,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0006295214004249"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2014.07.018","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR\u03b3): a review","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2014.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}